Enhanced Neutralizing Antibody Titers and Th1 Polarization from a Novel Escherichia coli Derived Pandemic Influenza Vaccine

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Skibinski, David A G ^a,b,g   Hanson, Brendon J ^c   Lin, Yufang ^b   von Messling, Veronika ^d   Jegerlehner, Andrea ^e   Tee, Jason Boon Sern ^c   Chye, De Hoe ^c   Wong, Steven K K ^c   Ng, Amanda A P ^a,b   Lee, Hui Yin ^b   Au, Bijin ^b   Lee, Bernett T K ^b   Santoso, Lucia ^f   Poidinger, Michael ^b   Fairhurst, Anna Marie ^b   Matter, Alex ^f   Bachmann, Martin F ^e,h   Saudan, Philippe ^e   Connolly, John E ^a,b,g  

^a AGENCY FOR SCIENCE   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c Defence Science Organisation (DSO) National Laboratories   (Singapore)

^d INRS INSTITUT ARMAND FRAPPIER   (Canada)

^e CYTOS BIOTECHNOLOGY AG   (Switzerland)

^f Agency for Science   (Singapore)

^g INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^h University Hospital Z rich   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; GAMMA INTERFERON; HEMAGGLUTININ; IMMUNOGLOBULIN G2A ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BACTERIOPHAGE; CELLULAR IMMUNITY; COVALENT BOND; CROSS LINKING; CYTOKINE PRODUCTION; DRUG FORMULATION; ESCHERICHIA COLI; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PROTEIN DOMAIN; SPLEEN CELL; TH1 CELL; VIRUS LIKE AGENT; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BACTERIOPHAGES; ESCHERICHIA COLI; FEMALE; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; MICE; ORTHOMYXOVIRIDAE INFECTIONS; RNA, BACTERIAL; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TH1 CELLS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84885803580     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076571     Document Type: Article

References (55)

1. Taubenberger JK, Morens DM, (2006) 1918 Influenza: the mother of all pandemics. Emerging Infect Dis 12: 15-22 doi:10.3201/eid1201.050979.
2. Rappuoli R, Dormitzer PR, (2012) Influenza: options to improve pandemic preparation. Science 336: 1531-1533 doi:10.1126/science.1221466.
3. Lambert LC, Fauci AS, (2010) Influenza vaccines for the future. N Engl J Med 363: 2036-2044 doi:10.1056/NEJMra1002842.
4. Murphy BR, Clements ML, (1989) The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 146: 107-116.
5. Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MMJ, et al. (2012) Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. Vaccine 30: 5407-5416 doi:10.1016/j.vaccine.2012.06.009.
6. Pushko P, Kort T, Nathan M, Pearce MB, Smith G, et al. (2010) Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 28: 4771-4776 doi:10.1016/j.vaccine.2010.04.093.
7. Liu G, Tarbet B, Song L, Reiserova L, Weaver B, et al. (2011) Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS ONE 6: e20928 doi:10.1371/journal.pone.0020928.
8. Iyer V, Liyanage MR, Shoji Y, Chichester JA, Jones RM, et al. (2012) Formulation development of a plant-derived h1n1 influenza vaccine containing purified recombinant hemagglutinin antigen. Hum Vaccin Immunother 8.
9. Wei C-J, Boyington JC, McTamney PM, Kong W-P, Pearce MB, et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060-1064 doi:10.1126/science.1192517.
10. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, et al. (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nature Biotechnology. doi:10.1038/nbt.2436.
11. Wilkinson TM, Li CKF, Chui CSC, Huang AKY, Perkins M, et al. (2012) Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nature Medicine 18: 274-280 doi:10.1038/nm.2612.
12. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, et al. (2006) T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176: 6333-6339.
13. McElhaney JE, (2005) The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23Suppl 1: S10-S25 doi:10.1016/j.vaccine.2005.04.019.
14. Arulanandam BP, Mittler JN, Lee WT, O'Toole M, Metzger DW, (2000) Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol 164: 3698-3704.
15. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, et al. (2006) Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13: 981-990 doi:10.1128/CVI.00156-06.
16. Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W, (1997) A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 71: 4347-4355.
17. Spohn G, Jennings GT, Martina BE, Keller I, Beck M, et al. (2010) A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J 7: 146 doi:10.1186/1743-422X-7-146.
18. Spohn G, Guler R, Johansen P, Keller I, Jacobs M, et al. (2007) A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 178: 7450-7457.
19. Spohn G, Keller I, Beck M, Grest P, Jennings GT, et al. (2008) Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 38: 877-887 doi:10.1002/eji.200737989.
20. Spohn G, Schwarz K, Maurer P, Illges H, Rajasekaran N, et al. (2005) Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol 175: 6211-6218.
21. Röhn TA, Jennings GT, Hernandez M, Grest P, Beck M, et al. (2006) Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 36: 2857-2867 doi:10.1002/eji.200636658.
22. Bachmann MF, Jennings GT, (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature Publishing Group 10: 787-796 doi:10.1038/nri2868.
23. Blander JM, Medzhitov R, (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440: 808-812 doi:10.1038/nature04596.
24. Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology.
25. Svitek N, Rudd PA, Obojes K, Pillet S, Messling von V, (2008) Severe seasonal influenza in ferrets correlates with reduced interferon and increased IL-6 induction. Virology 376: 53-59 doi:10.1016/j.virol.2008.02.035.
26. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck J-P, et al. (2006) Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29: 545-557 doi:10.1097/01.cji.0000211309.90621.8b.
27. Vence L, Palucka AK, Fay JW, Ito T, Liu Y-J, et al. (2007) Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci USA 104: 20884-20889 doi:10.1073/pnas.0710557105.
28. Chujo D, Foucat E, Takita M, Itoh T, Sugimoto K, et al. (2012) Emergence of a Broad Repertoire of GAD65-specific T Cells in Type 1 Diabetes Patients with Graft Dysfunction after Allogeneic Islet Transplantation. Cell Transplant. doi:10.3727/096368912X654993.
29. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, et al. (2007) TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 178: 2415-2420.
30. Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, et al. (2012) Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 42: 863-869 doi:10.1002/eji.201041225.
31. Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, et al. (2012) Innate immunity mediates follicular transport of particulate but not soluble protein antigen. The Journal of Immunology 188: 3724-3733 doi:10.4049/jimmunol.1103312.
32. Keller SA, Schwarz K, Manolova V, Allmen von CE, Kinzler MG, et al. (2010) Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. Eur J Immunol 40: 103-112 doi:10.1002/eji.200939559.
33. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, et al. (2009) Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 83: 5726-5734 doi:10.1128/JVI.00207-09.
34. Baras B, de Waal L, Stittelaar KJ, Jacob V, Giannini S, et al. (2011) Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets. Vaccine 29: 2120-2126 doi:10.1016/j.vaccine.2010.12.125.
35. Shaw A, (2012) New technologies for new influenza vaccines. Vaccine 30: 4927-4933 doi:10.1016/j.vaccine.2012.04.095.
36. Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H, et al. (1993) The influence of antigen organization on B cell responsiveness. Science 262: 1448-1451.
37. Chackerian B, Lowy DR, Schiller JT, (2001) Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108: 415-423 doi:10.1172/JCI11849.
38. Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, et al. (2002) Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol 32: 3305-3314 doi:;10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J.
39. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, et al. (2008) Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371: 821-827 doi:10.1016/S0140-6736(08)60381-5.
40. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, et al. (2005) A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35: 2031-2040 doi:10.1002/eji.200526285.
41. Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, et al. (2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25: 63-72 doi:10.1097/HJH.0b013e32800ff5d6.
42. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, et al. (2008) A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 3: e2547 doi:10.1371/journal.pone.0002547.
43. Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, et al. (2006) Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 117: 1470-1476 doi:10.1016/j.jaci.2006.01.040.
44. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, et al. (2012) Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11: 597-604 doi:10.1016/S1474-4422(12)70140-0.
45. Guarnaccia T, Carolan LA, Maurer-Stroh S, Lee RTC, Job E, et al. (2013) Antigenic Drift of the Pandemic 2009 A(H1N1) Influenza Virus in a Ferret Model. PLoS Pathog 9: e1003354 doi:10.1371/journal.ppat.1003354.
46. World Health Organization (2012) Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season-February 2012.
47. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL, (2010) Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol 84: 9217-9226 doi:10.1128/JVI.01069-10.
48. McKinstry KK, Strutt TM, Kuang Y, Brown DM, Sell S, et al. (2012) Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J Clin Invest 122: 2847-2856 doi:10.1172/JCI63689.
49. Seo SH, Webster RG, (2002) Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol 76: 1071-1076.
50. Hocart MJ, Mackenzie JS, Stewart GA, (1989) The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J Gen Virol 70 (Pt 9): 2439-2448.
51. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG, (2006) Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194: 159-167 doi:10.1086/505225.
52. Vela EM, Buccellato MA, Tordoff K, Stark G, Bigger JE, (2012) Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1. Influenza Other Respi Viruses 6: 328-340 doi:10.1111/j.1750-2659.2011.00321.x.
53. Davenport FM, Hennessy AV, Askin FB, (1968) Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man. J Immunol 100: 1139-1140.
54. Bresson J-L, Perronne C, Launay O, Gerdil C, Saville M, et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367: 1657-1664 doi:10.1016/S0140-6736(06)68656-X.
55. Treanor J, Keitel W, Stephenson I (2009) Chapter 51: Influenza. New Generation Vaccines. New Generation Vaccines. Informa HealthCare.